PTHrP/MET axis in the aggressive behavior of colorectal cancer cells.

CARRIERE PEDRO MATÍAS; ZWENGER ARIEL; BIRKENSTOCK CONTIA; GIGOLA G; GENTILI, CLAUDIA; NOVOA DÍAZ BELEN; GOMEZ LUIS; CALVO, NATALIA

Mar del Plata

Congreso; LXVII Reunión Anual de Sociedades de Biociencias (SAIC); 2022

Sociedad Argentina de Investigación Clínica

Met receptor is involved in the progression of colorectal cancer (CRC). Parathyroid hormone-related peptide (PTHrP) is a cytokine from the tumor and its microenvironment associated with the aggressiveness of different types of cancer. Previously, we found in HCT116 cells from CRC that the binding of PTHrP to its receptor (PTHR1) favors chemoresistance to drugs employed in CRC treatment and other events associated with an aggressive phenotype. PTHrP diminished the sensitivity of these drugs through Met. In HCT116 cells xenografts, PTHrP modulates markers expression linked to tumor progression including Met. The aim of this work is to further investigate the relationship between PTHR1, PTHrP and Met in CRC models. Using SU11274, the Met specific inhibitor, and the following techniques: western blot, wound healing assay and monitoring morphological changes we observed the reversal of cell migration (p